|
SIRT5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.44349999731119E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.42470000025408E-07 |
| Normal-vs-Stage2 |
5.459800E-01 |
| Normal-vs-Stage3 |
4.01380040315757E-10 |
| Normal-vs-Stage4 |
2.31090000468726E-08 |
| Stage1-vs-Stage2 |
5.536800E-03 |
| Stage1-vs-Stage3 |
8.016000E-03 |
| Stage1-vs-Stage4 |
1.612210E-02 |
| Stage2-vs-Stage3 |
2.19849999999466E-05 |
| Stage2-vs-Stage4 |
1.575700E-04 |
| Stage3-vs-Stage4 |
7.753200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06069997229952E-09 |
| Normal-vs-AfricanAmerican |
5.431000E-04 |
| Normal-vs-Asian |
4.720100E-03 |
| Caucasian-vs-AfricanAmerican |
8.142000E-01 |
| Caucasian-vs-Asian |
5.437800E-02 |
| AfricanAmerican-vs-Asian |
3.076600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.27629999960399E-07 |
| Normal-vs-Female |
4.95070000550157E-08 |
| Male-vs-Female |
5.070200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.82610000010186E-07 |
| Normal-vs-Age(41-60Yrs) |
2.60239999994027E-07 |
| Normal-vs-Age(61-80Yrs) |
2.48810000003097E-06 |
| Normal-vs-Age(81-100Yrs) |
5.388200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.716200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.942200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.461000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.223200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.072600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.281000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.52570000003338E-06 |
| Classical-VS-Follicular |
5.47179999976777E-07 |
| Classical-VS-Other |
2.834400E-01 |
| Classical-VS-Normal |
2.45869999915271E-08 |
| Tall-VS-Follicular |
7.78832554004794E-12 |
| Tall-VS-Other |
8.962200E-04 |
| Tall-VS-Normal |
1.83408843668076E-12 |
| Follicular-VS-Other |
5.943200E-01 |
| Follicular-VS-Normal |
2.192000E-01 |
| Other-VS-Normal |
1.967760E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.85270999999432E-05 |
| Normal-vs-N1 |
1.73719999496669E-08 |
| N0-vs-N1 |
5.595200E-03 |
|
|
